Brokerages predict that Jazz Pharmaceuticals plc (NASDAQ:JAZZ) will announce $863.72 million in sales for the current quarter, according to Zacks. Seven analysts have issued estimates for Jazz Pharmaceuticals’ earnings, with the highest sales estimate coming in at $877.05 million and the lowest estimate coming in at $852.75 million. Jazz Pharmaceuticals reported sales of $665.52 million in the same quarter last year, which indicates a positive year-over-year growth rate of 29.8%. The business is expected to announce its next quarterly earnings results on Tuesday, February 22nd.
According to Zacks, analysts expect that Jazz Pharmaceuticals will report full year sales of $3.06 billion for the current fiscal year, with estimates ranging from $3.05 billion to $3.07 billion. For the next fiscal year, analysts expect that the company will post sales of $3.63 billion, with estimates ranging from $3.53 billion to $3.80 billion. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Jazz Pharmaceuticals.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, November 9th. The specialty pharmaceutical company reported $4.20 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.60 by $1.60. Jazz Pharmaceuticals had a positive return on equity of 21.43% and a negative net margin of 5.62%. The business had revenue of $838.12 million for the quarter, compared to the consensus estimate of $829.98 million. During the same quarter last year, the business posted $3.86 EPS.
In other news, SVP Finbar Larkin sold 197 shares of the business’s stock in a transaction dated Friday, November 12th. The shares were sold at an average price of $135.79, for a total value of $26,750.63. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bruce C. Cozadd sold 6,556 shares of the business’s stock in a transaction dated Monday, November 1st. The shares were sold at an average price of $134.75, for a total transaction of $883,421.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 16,162 shares of company stock worth $2,146,536. Insiders own 4.30% of the company’s stock.
Several large investors have recently modified their holdings of JAZZ. Oppenheimer Asset Management Inc. increased its stake in Jazz Pharmaceuticals by 1.2% in the second quarter. Oppenheimer Asset Management Inc. now owns 5,665 shares of the specialty pharmaceutical company’s stock valued at $1,006,000 after acquiring an additional 65 shares during the last quarter. Neuberger Berman Group LLC boosted its holdings in shares of Jazz Pharmaceuticals by 3.8% in the 2nd quarter. Neuberger Berman Group LLC now owns 2,000 shares of the specialty pharmaceutical company’s stock valued at $330,000 after purchasing an additional 73 shares in the last quarter. Confluence Investment Management LLC increased its stake in shares of Jazz Pharmaceuticals by 2.7% in the 3rd quarter. Confluence Investment Management LLC now owns 3,178 shares of the specialty pharmaceutical company’s stock valued at $414,000 after purchasing an additional 84 shares during the last quarter. Daiwa Securities Group Inc. raised its holdings in shares of Jazz Pharmaceuticals by 3.0% during the 3rd quarter. Daiwa Securities Group Inc. now owns 3,106 shares of the specialty pharmaceutical company’s stock worth $404,000 after buying an additional 90 shares in the last quarter. Finally, Kestra Advisory Services LLC lifted its position in shares of Jazz Pharmaceuticals by 3.1% during the 3rd quarter. Kestra Advisory Services LLC now owns 3,095 shares of the specialty pharmaceutical company’s stock worth $403,000 after buying an additional 93 shares during the last quarter. Institutional investors own 91.42% of the company’s stock.
Shares of NASDAQ JAZZ traded down $0.24 during mid-day trading on Friday, reaching $129.31. 288,927 shares of the company’s stock were exchanged, compared to its average volume of 681,663. Jazz Pharmaceuticals has a twelve month low of $126.01 and a twelve month high of $189.00. The company has a current ratio of 3.58, a quick ratio of 2.03 and a debt-to-equity ratio of 1.59. The firm has a market capitalization of $7.95 billion, a price-to-earnings ratio of -50.71, a PEG ratio of 0.69 and a beta of 0.91. The business has a fifty day simple moving average of $134.84 and a 200 day simple moving average of $154.25.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca.
Read More: Example of operating income, EBIT and EBITDA
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.